Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
25.18M | 16.03M | 8.59M | 5.45M | 3.50M | Gross Profit |
21.40M | 13.23M | 6.98M | 4.07M | 1.76M | EBIT |
-12.16M | -18.80M | -22.87M | -20.04M | -24.28M | EBITDA |
-10.90M | -17.76M | -22.33M | -19.66M | -24.18M | Net Income Common Stockholders |
-11.89M | -18.83M | -22.16M | -17.22M | -23.51M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
11.97M | 10.33M | 17.71M | 34.69M | 22.63M | Total Assets |
20.47M | 16.10M | 24.76M | 42.83M | 31.52M | Total Debt |
4.14M | 626.00K | 699.00K | 760.87K | 2.99M | Net Debt |
686.00K | -9.71M | -17.01M | -33.93M | -1.25M | Total Liabilities |
12.93M | 8.66M | 7.67M | 6.18M | 7.87M | Stockholders Equity |
7.54M | 7.44M | 17.09M | 36.65M | 23.64M |
Cash Flow | Free Cash Flow | |||
-6.95M | -14.87M | -16.64M | -13.63M | -20.10M | Operating Cash Flow |
-6.95M | -14.67M | -16.64M | -13.63M | -20.10M | Investing Cash Flow |
-8.52M | -206.00K | 0.00 | 18.22M | -7.96M | Financing Cash Flow |
8.44M | 7.49M | 0.00 | 25.68M | 18.95M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $102.37M | ― | -16.53% | ― | -4.15% | 3.49% | |
58 Neutral | $36.88M | ― | -276.15% | ― | 41.54% | 42.59% | |
58 Neutral | $58.75M | ― | -52.88% | ― | ― | 29.64% | |
54 Neutral | $58.20M | ― | -130.26% | ― | -6.27% | 16.76% | |
53 Neutral | $5.14B | 3.03 | -43.89% | 2.83% | 16.75% | -0.06% | |
50 Neutral | $56.96M | ― | -267.29% | ― | 12.78% | 15.53% |
On May 2, 2025, electroCore, Inc. announced the completion of its merger with NeuroMetrix, Inc., which positions electroCore as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, enhances its commercial reach, particularly within the VA Hospital System, and is expected to significantly increase its addressable market for chronic pain and wellness conditions. As a result of the merger, NeuroMetrix became an indirect wholly-owned subsidiary of electroCore, and its shares will be de-listed from the Nasdaq Capital Market.
On February 24, 2025, Charles S. Theofilos, M.D., resigned from his roles at Electrocore, Inc., including his position as a Class III director and memberships in the Compensation and Nominating and Governance Committees. Following his resignation, the Board reduced its size from eight to seven members, effective February 28, 2025.